At the Oncology Forum 2025, host Sanjay Juneja, MD, led a dynamic discussion with panelists Tian Zhang, MD, Petros Grivas, MD, PhD, and Karine Tawagi, MD, covering pivotal developments across genitourinary cancers.
The panel explored late-breaking data on PARP inhibitors in metastatic castrate-sensitive prostate cancer, BCG-naïve non–muscle-invasive bladder cancer trials like CREST, and the potential of EV/pembrolizumab in metastatic urothelial carcinoma. The session highlighted both clinical enthusiasm and emerging questions around treatment sequencing, patient selection, and long-term outcomes.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.